Camber Pharmaceuticals, Inc. received FDA approval for Abbreviated New Drug Application #211487 covering hydrocodone bitartrate and acetaminophen oral tablets on November 7, 2018. This development expands the manufacturer's generic footprint, adding a new competitor to the market for this widely prescribed combination therapy that could contribute to competitive price dynamics.